摘要
玻璃体腔注射抗血管内皮生长因子(VEGF)药物是目前临床上治疗早产儿视网膜病变(ROP)的一线疗法,具有操作方便、起效快、不良反应小等优势,但在临床应用中可观察到有较高的复活率,限制了其临床应用。正确认识复活的特征对管理患者和开展临床试验具有重要意义,ROP国际分类法第3版更新了关于复活的定义及相关概念。本文总结近年来各研究中抗VEGF药物治疗ROP后复活的临床表现和机制,并进一步分析与复活相关的高危因素,包括患儿、疾病和药物方面,以期为临床上能尽早识别并及时进行预防和干预提供指导。但对于ROP复活的预防及再治疗,目前临床上尚存在较大争议,未来需积累更多的循证医学证据和进行更大规模的前瞻性研究,从而进一步规范诊疗过程。
The intravitreal injection of anti-vascular endothelial growth factor(VEGF)agents is currently the first-line therapy for retinopathy of prematurity(ROP)in clinical practice.This therapy has several advantages,including ease of operation,rapid onset of action,and minimal adverse reactions.However,the high reactivation rate observed in clinical applications limits its utility.Understanding reactivation characteristics is crucial for patient management and clinical trial design.The International Classification of Retinopathy of Prematurity(Third edition)updated the definition of reactivation and related concepts.This article summarizes the clinical manifestations and mechanisms of ROP reactivation after anti-VEGF therapy in recent studies and analyzes high-risk factors associated with reactivation,including those related to the infant,the disease,and the medication.The goal is to provide guidance for the early identification,prevention,and intervention in clinical practice.Nevertheless,significant clinical controversies remain regarding the prevention and retreatment of ROP reactivation.Future research should accumulate more evidence-based medical data and conduct large-scale prospective studies to further standardize diagnostic and treatment processes.
作者
钟育晟(综述)
梁建宏
黎晓新
程湧(审校)
Zhong Yusheng;Liang Jianhong;Li Xiaoxin;Cheng Yong(Department of Ophthalmology,Peking University People's Hospital,Beijing Key Laboratory of Ocular Disease and Optometry Science,Beijing 100044,China)
出处
《中华实验眼科杂志(中英文)》
北大核心
2025年第8期761-765,共5页
Chinese Journal Of Experimental Ophthalmology
基金
北京大学人民医院研究与发展基金(RDL2024-09)。
关键词
早产儿视网膜病变
血管内皮生长因子
复活
预防
治疗
综述
Retinopathy of prematurity
Vascular endothelial growth factor
Reactivation
Prevention
Treatment
Review
作者简介
通信作者:程湧,Email:raccocheng@126.com。
